Abdominal or Thoracic Aortic Aneurysm Surgery | MyMedicPlus — Cost, Top Hospitals & Success Rates | MyMedicPlus

An aortic aneurysm is a localised, pathological dilatation of the aorta — the body's largest artery — exceeding 1.5 times its normal diameter. Aneurysms most commonly develop in the infrarenal abdominal aorta (abdominal aortic aneurysm, AAA), affecting approximately 3–9% of men over 65 and 1–2% of women. Thoracic aortic aneurysms (TAA) involve the aorta within the chest and may affect the ascending aorta, aortic arch, or descending thoracic aorta, with distinct anatomical challenges and surgical implications for each segment. Thoracoabdominal aortic aneurysms (TAAA) extend from the chest into the abdomen and represent the most complex surgical challenge in vascular surgery.

The natural history of aortic aneurysms is one of progressive enlargement driven by degradation of the aortic wall's elastic and collagen architecture — mediated by matrix metalloproteinases, inflammatory infiltrates, and haemodynamic wall stress. The critical risk of an untreated aneurysm is rupture, which carries an overall mortality exceeding 80%. For AAA, rupture risk increases non-linearly with diameter: aneurysms below 5 cm have an annual rupture risk below 1%, rising to 6–11% per year at 6 cm and 30–50% per year above 7 cm. Elective repair before aneurysm enlargement to dangerous dimensions virtually eliminates rupture risk.

Diagnosis is established by cross-sectional imaging. Ultrasound is the preferred AAA screening tool, offering real-time diameter measurement without radiation. CT angiography (CTA) provides definitive three-dimensional anatomical characterisation of aneurysm morphology, extent, relationship to visceral arteries (renal, mesenteric, iliac branches), and neck geometry — all critical for treatment planning. MR angiography offers equivalent detail without radiation for patients with contrast contraindications. Repair is indicated when the AAA diameter reaches 5.5 cm in men (5.0–5.4 cm in women), when the growth rate exceeds 1 cm per year, or when the aneurysm becomes symptomatic with pain or tenderness regardless of size.

Modern aortic aneurysm repair offers two principal approaches: conventional open surgical repair, which has been performed for over 60 years with well-established long-term durability, and endovascular aortic repair (EVAR for abdominal, TEVAR for thoracic), which deploys a fabric-covered metal stent-graft inside the aneurysm via catheter-based access through the femoral arteries, excluding the aneurysm sac from arterial circulation. At experienced aortic centres, both approaches are available, and treatment selection is individualised based on anatomical suitability, patient fitness, and expected long-term outcomes.

The primary indication for aortic aneurysm surgery is a large or rapidly growing aortic aneurysm meeting size thresholds for repair. Elective AAA repair is recommended at 5.5 cm (men) or 5.0 cm (women), or when growth exceeds 1 cm per year on serial imaging. Symptomatic AAA — presenting with new abdominal or back pain from aneurysm expansion, distal embolisation causing limb or visceral ischaemia, or aortoenteric fistula — requires urgent repair regardless of size. Ruptured AAA is a surgical emergency with extremely high mortality requiring immediate intervention.

Thoracic aortic aneurysms are repaired at 5.5 cm for atherosclerotic descending TAA (or 6.0 cm for ascending TAA not associated with a bicuspid aortic valve or connective tissue disorder). Patients with Marfan syndrome, Loeys-Dietz syndrome, or bicuspid aortic valve disease are repaired at smaller diameters (4.5–5.0 cm) because their aortic wall is inherently weaker and rupture risk occurs at smaller sizes. Aortic dissection — a distinct condition involving a tear in the aortic intima — may be treated with TEVAR when it involves the descending thoracic aorta and is complicated by malperfusion, aneurysmal dilatation, or persistent pain. Penetrating aortic ulcers and intramural haematoma are managed by similar endovascular or surgical principles.

Ideal candidates for elective EVAR are patients with infrarenal AAA meeting size criteria whose CT anatomy demonstrates an adequate infrarenal aortic neck (length above 15 mm, diameter below 32 mm, angulation below 60 degrees), suitable iliac artery access, and absence of severe neck calcification or thrombus. EVAR carries significantly lower 30-day mortality (approximately 1–2%) compared to open repair (2–5%) and shorter recovery, making it preferred for elderly patients with significant cardiorespiratory comorbidities. Open repair is considered when EVAR anatomy is unfavourable, when the patient is young and physiologically robust (where long-term durability of open repair is advantageous), or when juxtarenal or suprarenal aneurysm extent requires renal artery reimplantation incompatible with standard EVAR devices.

Contraindications to elective aortic repair include patients whose operative risk (severe COPD with FEV1 below 1L, severe cardiac dysfunction with ejection fraction below 30%, advanced renal failure, or severe pulmonary hypertension) makes perioperative mortality likely to exceed the aneurysm rupture risk over the foreseeable lifespan. These patients are managed conservatively with aggressive cardiovascular risk factor modification (smoking cessation, antihypertensive therapy, statins) and periodic surveillance imaging. Active infection (mycotic aneurysm) requires antibiotic treatment before or concurrent with surgery, as standard graft implantation in an infected field carries high risk of graft infection and aortoenteric fistula.

Open surgical repair of AAA involves a transperitoneal or retroperitoneal approach, clamping the aorta above and below the aneurysm, opening the aneurysm sac, and sewing in a tubular or bifurcated Dacron or PTFE graft. The aneurysm sac is then wrapped around the graft. The retroperitoneal approach is preferred in patients with prior abdominal surgery, horseshoe kidney, or hostile abdomen. Open repair provides lifelong durability without the need for post-operative surveillance imaging, its main advantage over EVAR. For thoracic and thoracoabdominal aneurysms, open surgery requires cardiopulmonary bypass, cerebrospinal fluid (CSF) drainage to prevent spinal cord ischaemia, and sequential clamping techniques to minimise visceral ischaemia.

Endovascular aortic repair (EVAR) for infrarenal AAA deploys a modular stent-graft system through bilateral femoral artery access under fluoroscopic guidance. The main body and iliac limb components are delivered sequentially to create an internal bypass excluding the aneurysm sac from systemic blood pressure, allowing the sac to thrombose and shrink. EVAR typically takes two to three hours, requires only regional or spinal anaesthesia in some centres, and is associated with significantly shorter hospital stay and faster recovery than open repair. Thoracic endovascular aortic repair (TEVAR) for descending TAA delivers a stent-graft via femoral or iliac access, covering the aneurysm segment and diverting blood flow through the endoprosthesis.

Fenestrated and branched EVAR (FEVAR, BEVAR) extends endovascular technology to juxtarenal and thoracoabdominal aneurysms by incorporating custom-manufactured fenestrations and branches in the stent-graft to maintain perfusion to the renal, mesenteric, and celiac arteries. These complex endovascular techniques are performed at specialist aortic centres and represent the frontier of minimally invasive vascular repair for high-risk patients whose anatomy previously mandated complex open surgery.

Successful elective aortic aneurysm repair effectively eliminates the risk of aneurysm rupture, which would otherwise carry over 80% mortality. The 30-day mortality for elective EVAR at high-volume centres is approximately 0.5–1.5%, and for elective open repair 2–5% — both far below the mortality risk of rupture. Long-term survival following successful elective repair is comparable to age-matched controls without aneurysm, as the life-threatening aortic pathology has been definitively addressed. Patients undergoing EVAR experience significantly less perioperative morbidity, shorter ICU and total hospital stay (median 2–3 days versus 7–10 days for open repair), faster return to normal activity (2–3 weeks versus 6–8 weeks), and reduced blood loss and transfusion requirements.

Aneurysm sac regression — measured by CT surveillance imaging at 1 month, 1 year, and annually thereafter — occurs in over 60–70% of EVAR patients, confirming successful aneurysm exclusion. Five-year freedom from aneurysm-related death is approximately 95% after EVAR in anatomically suitable patients at experienced centres. Open repair provides comparable freedom from aneurysm-related death over 10+ years without the ongoing need for CT surveillance. For ruptured AAA reaching the operating table, emergency open or endovascular repair provides salvage rates of 40–60%, representing a dramatic improvement from the natural history of untreated rupture.

Endoleaks — persistent blood flow into the aneurysm sac outside the stent-graft — are the characteristic complication of EVAR, occurring in 10–15% of cases. Type I endoleaks (at the proximal or distal attachment zones) and Type III endoleaks (from graft junctions) are haemodynamically significant and require prompt re-intervention, typically by angiographic balloon dilation, extension cuff placement, or open conversion. Type II endoleaks from retrograde filling via lumbar or inferior mesenteric arteries are the most common (30–40%) but usually benign, resolving spontaneously or requiring coil embolisation only when associated with sac enlargement. Stent-graft migration, kinking, and limb thrombosis are additional long-term EVAR complications necessitating radiological surveillance.

Open surgical repair carries risks of myocardial infarction (3–8%), renal impairment (8–15%), pulmonary complications (10–20%), wound infection, ileus, and sexual dysfunction from injury to the pre-aortic autonomic plexus. Spinal cord ischaemia causing paraplegia occurs in approximately 0.25% of infrarenal AAA repairs and up to 5–10% of thoracoabdominal repairs — the most feared neurological complication, mitigated by CSF drainage protocols, staged clamping, and motor-evoked potential monitoring. Aortoenteric fistula between the graft and duodenum is a rare but devastating late complication requiring complex surgical management. Overall, EVAR has lower 30-day mortality but higher late re-intervention rates than open repair, while open repair has higher perioperative risk but greater long-term durability.

Following EVAR, patients are monitored in the ICU or high-dependency unit overnight and typically discharged on day two to three. Groin access site wounds are checked at one to two weeks. Lifelong CT surveillance is essential after EVAR — CT angiography at one month, six months, and twelve months post-procedure, then annually thereafter — to detect endoleaks, stent-graft migration, and aneurysm sac size changes. Access to a vascular surgery centre for re-intervention must remain available throughout the patient's lifetime. Activity restrictions include avoiding heavy lifting above 5 kg for four to six weeks; most patients return to light activities within two weeks and full activity within four weeks.

Following open repair, patients typically spend two to three days in the ICU and five to seven additional days on the ward. Full recovery to normal activities requires six to eight weeks, with lifting restrictions of eight to twelve weeks. Bowel function recovery after transperitoneal approach takes three to five days. Long-term follow-up after open repair requires abdominal ultrasound every five years to exclude anastomotic false aneurysm, but does not mandate annual CT scanning as the aneurysm is definitively excluded. All patients following aortic repair require lifelong aggressive cardiovascular risk factor management including antiplatelet therapy, statin therapy, antihypertensive control targeting systolic BP below 120–130 mmHg, and smoking cessation to protect the repaired aorta and reduce overall cardiovascular risk.

Aortic aneurysm surgery is among the most expensive vascular procedures. In the United States, elective EVAR costs $35,000–$65,000 including device, hospital stay, and surgeon fees; open AAA repair costs $30,000–$55,000. Thoracoabdominal aneurysm repair at major academic centres in the US can exceed $100,000–$150,000. In the United Kingdom under the NHS, these procedures are covered, but private surgical care costs £15,000–£35,000 for EVAR and £20,000–£40,000 for open repair. Emergency ruptured AAA repair costs significantly more due to ICU requirements.

Medical tourism for elective aortic aneurysm surgery is available at JCI-accredited specialist cardiovascular centres in India, Turkey, and Thailand at 60–75% lower cost. In India, elective EVAR costs approximately $8,000–$15,000 at premier cardiac centres in Chennai, Mumbai, and Hyderabad using internationally approved endovascular devices (Gore Excluder, Medtronic Endurant, Cook Zenith). Open AAA repair is available at $6,000–$12,000. These centres have experienced vascular surgeons trained at leading Western institutions, access to the full range of endovascular devices, and dedicated vascular ICU facilities. Given the critical nature of aortic surgery and the requirement for lifelong CT surveillance following EVAR, patients must ensure continuity of follow-up care with a vascular surgery centre in their home country.

For patients with small aneurysms below the threshold for repair, conservative management with surveillance ultrasound every six to twelve months (depending on size) and aggressive cardiovascular risk modification is the standard of care. Statins have been shown in retrospective studies to reduce aneurysm growth rate by approximately 30%, and antihypertensives — particularly doxazosin and beta-blockers — are recommended for their cardiovascular protective effects even if direct aneurysm growth inhibition has not been definitively proven in randomised trials. Smoking cessation is the single most important modifiable risk factor for aneurysm expansion and rupture and should be supported with pharmacological aids.

For elderly or extremely high-risk patients in whom the operative risk of either EVAR or open repair exceeds the aneurysm rupture risk, palliation with pain management and conservative care represents an ethical alternative when patients have been fully counselled on their options. Fenestrated EVAR and branched EVAR have expanded the proportion of patients who can be treated endovascularly (now approximately 80–85% of AAA cases), reducing the need for high-risk open surgery in anatomically complex cases. Investigational medical therapies targeting matrix metalloproteinase inhibition (doxycycline) and aortic wall inflammation have shown some promise in reducing aneurysm growth in small trials but are not yet standard clinical practice.